SCHEMBL328994

SCHEMBL328994

Cc1ccc(C(=O)N=C=NC(=O)c2ccc(C)cc2)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.52
CES2 O00748 3/20 0.52
CES1 P23141 3/20 0.52
LMNA P02545 3/20 0.52
SMN1; SMN2 Q16637 3/20 0.50
TDP1 Q9NUW8 3/20 0.46
HTT P42858 3/20 0.46
NPSR1 Q6W5P4 3/20 0.46
PKM P14618 3/20 0.46
KMT2A Q03164 3/20 0.46
ATM Q13315 2/20 0.46
HPGD P15428 2/20 0.46
MEN1 O00255 2/20 0.46
NLRP1 Q9C000 1/20 0.46
GAA P10253 1/20 0.46
NTSR1 P30989 1/20 0.46
NPC1 O15118 3/20 0.45
RAB9A P51151 3/20 0.45
MAPT P10636 3/20 0.45
MAPK1 P28482 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL811028 0.84 ALDH1A1 (0.50) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL1557844 0.83 ALDH1A1 (0.48) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL2892447 0.83 ALDH1A1 (0.48) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL1772947 0.82 CES2 (0.47) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL5200457 0.79 ALDH1A1 (0.45) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL5691184 0.78 ALDH1A1 (0.59) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL1774091 0.78 NPC1 (0.45) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL13536412 0.76 ALDH1A1 (0.56) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL4269458 0.76 ALDH1A1 (0.56) ALDH1A1CES2CES1LMNASMN1; SMN2
SCHEMBL16358251 0.74 ALDH1A1 (0.54) ALDH1A1CES2CES1LMNASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 508 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250332824-A1 ADHESIVE BACKED HYDROLYSIS-RESISTANT WINDOW FILM GARWARE HI-TECH FILMS LIMITED (IN) 2025-10-30 US claimed
US-20220143963-A1 ADHESIVE BACKED HYDROLYSIS-RESISTANT WINDOW FILM GARWARE HI-TECH FILMS LIMITED (IN) 2022-05-12 US claimed
US-11292890-B2 Curable resin composition and sealing material using same NIPPON SHOKUBAI CO., LTD. (JP) 2022-04-05 US claimed
US-20180134947-A1 METHODS FOR TREATING HIGH TEMPERATURE SUBTERRANEAN FORMATIONS SCHLUMBERGER TECHNOLOGY CORPORATION 2018-05-17 US claimed
WO-2016159817-A1 METHODS FOR TREATING HIGH TEMPERATURE SUBTERRANEAN FORMATIONS SCHLUMBERGER CANADA LIMITED (CA) 2016-10-06 WO claimed
US-9309356-B2 Method for activating double metal cyanide catalysts for the production of polyether carbonate polyols BAYER INTELLECTUAL PROPERTY GMBH (DE) 2016-04-12 US claimed
EP-2734567-B1 METHOD FOR ACTIVATING DOUBLE METAL CYANIDE CATALYSTS FOR THE PRODUCTION OF POLYETHER CARBONATE POLYOLS BAYER IP GMBH (DE) 2015-09-09 EP claimed
US-20140221602-A1 METHOD FOR ACTIVATING DOUBLE METAL CYANIDE CATALYSTS FOR THE PRODUCTION OF POLYETHER CARBONATE POLYOLS BAYER INTELLECTUAL PROPERTY GMBH (DE) 2014-08-07 US claimed
EP-2548905-A1 Method for activating double metal cyanide catalysts to produce polyether polyols Bayer MaterialScience AG (DE) 2013-01-23 EP claimed
US-5834273-A URICASE MODIFIED BY REACTING WITH POLYAMINO ACID CONTAINING GLUTAMIC ACID OR ASPARTIC ACID RESIDUES WAKO PURE CHEMICAL INDUSTRIES, LTD. (JP) 1998-11-10 US claimed
EP-4747282-A1 ACTIVATABLE TYROSINE-PROTEIN KINASE MEMBRANE RECEPTOR (ROR) ANTIBODY-DRUG CONJUGATES AND USES THEREOF Exelixis, Inc. (US) 2026-05-27 EP disclosed
EP-4747283-A1 TYROSINE-PROTEIN KINASE MEMBRANE RECEPTOR 1 (ROR1) ANTIBODY-DRUG CONJUGATES AND USES THEREOF Exelixis, Inc. (US) 2026-05-27 EP disclosed
EP-4746922-A2 INTERLEUKIN-13 RECEPTOR SUBUNIT ALPHA-2 ANTIBODY-DRUG CONJUGATES AND USES THEREOF Exelixis, Inc. (US) 2026-05-27 EP disclosed
US-12640420-B2 Aluminum pouch film for secondary battery, and method for manufacturing same SBTL ADVANCED MATERIALS CO., LTD. (KR) 2026-05-26 US disclosed
US-20260083856-A1 THIAZOLIDINE LINKERS FOR PROTEIN-DRUG CONJUGATES AND USES THEREOF SCHERER TECHNOLOGIES LLC R P (US) 2026-03-26 US disclosed
US-4871589-A PRETREATMENT IMMERSION INTO ETHYLENIMINE, CARBODIIMIDE OR DERIVATIVES; BONDING STRENGTH SUMITOMO RUBBER INDUSTRIES, LTD. (JP) 1989-10-03 US disclosed
US-4518802-A IMMUNOSTIMULANT ZAIDAN HOJIN BISEIBUTSU KAGAKU KENKYU KAI (JP) 1985-05-21 US disclosed
US-4238391-A AMIDATION OF BLEOMYCINIC ACID NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1980-12-09 US disclosed
US-4195018-A CARCINOSTATIC ANTIBIOTICS NIPPON KAYAKU KABUSHIKI KAISHA (JP) 1980-03-25 US disclosed
US-4164114-A PET AND ANOTHER POLYESTER, RUBBER REINVORCEMENT, DURABILITY Toyobo Petcord, Co., Ltd. (JP) 1979-08-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260083856-A1 THIAZOLIDINE LINKERS FOR PROTEIN-DRUG CONJUGATES AND USES THEREOF BRWD1, TMIGD3, TXNL1 ALDH1A1 556/4885CES2 3204/4885CES1 2128/4885
US-12640420-B2 Aluminum pouch film for secondary battery, and method for manufacturing same KDM2B, AFF2, MLN ALDH1A1 1534/4885CES2 3907/4885CES1 4437/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.